Related Experiment Video
Updated: Feb 15, 2026

Murine Orchiectomy and Ovariectomy to Reduce Sex Hormone Production
Published on: November 17, 2023
Structure-based development of an osteoprotegerin-like glycopeptide that blocks RANKL/RANK interactions and reduces
Chao Liu1, Xiao Chen2, Xin Zhi3
1Department of Organic Chemistry, College of Pharmacy, Second Military Medical University, Shanghai 200433, China.
Abstract:
Osteoporosis is a metabolic bone disease characterized by low bone mass and micro-architectural deterioration of bone, for which the underlying mechanism is an imbalance between bone resorption and bone remodeling. The protein-protein interactions between receptor activator of nuclear factor-κB ligand (RANKL), RANK (its receptor), and osteoprotegerin (OPG), are known to mediate the development and activation of osteoclasts in bone remodeling, and are regarded as a pivotal therapeutic target for the treatment of osteoporosis. Herein, we disclose the successful development of a novel glycopeptide (OM-2), the structure of which is based on the key interacting sites of the reported RANKL and OPG crystal structure. OM-2 exhibited potent binding affinity with RANKL and resistance to degradation by protease enzymes. It also blocked RANKL/RANK interactions, and inhibited osteoclastogenesis in vitro. In vivo studies confirmed that OM-2 could effectively reduce bone loss and inhibit osteoclast activation in ovariectomized (OVX) mice at a dosage of 20.0 mg/kg/day. Accordingly, OM-2 is suggested as a therapeutic candidate for postmenopausal osteoporosis (PMOP) and osteoclastogenesis-related diseases like rheumatoid arthritis (RA). More importantly, its identification validates our structure-based strategy for the development of drugs that target the RANKL/RANK/OPG system.
Insights
A novel glycopeptide, OM-2, effectively targets the RANKL/RANK/OPG system to inhibit osteoclastogenesis. This promising therapeutic candidate shows potential for treating osteoporosis and related bone diseases.
Area of Science:
- Biochemistry
- Pharmacology
- Bone Biology
Background:
- Osteoporosis is a metabolic bone disease driven by imbalanced bone remodeling.
- The RANKL/RANK/OPG pathway is crucial for osteoclast development and a key therapeutic target.
Purpose of the Study:
- To develop a novel glycopeptide (OM-2) targeting the RANKL/RANK/OPG system.
- To evaluate OM-2's efficacy in preclinical models of osteoporosis.
Main Methods:
- Structure-based drug design utilizing RANKL and OPG crystal structures.
- In vitro assays for binding affinity, protease resistance, and osteoclastogenesis inhibition.
- In vivo studies in ovariectomized (OVX) mice to assess bone loss and osteoclast activity.
Main Results:
- OM-2 demonstrated strong binding to RANKL and resistance to enzymatic degradation.
- OM-2 effectively blocked RANKL/RANK interactions and inhibited osteoclastogenesis in vitro.
- In vivo, OM-2 significantly reduced bone loss and osteoclast activation in OVX mice.
Conclusions:
- OM-2 is a potent therapeutic candidate for postmenopausal osteoporosis and other osteoclastogenesis-related diseases.
- The study validates a structure-based strategy for targeting the RANKL/RANK/OPG system.
- OM-2 shows promise for treating conditions like rheumatoid arthritis.
More Related Videos
Related Concept Videos
Reducing Line Loss
With a step-up transformer at the source, the voltage is increased, thereby reducing the current in the transmission lines since power loss in...
Adaptations that Reduce Water Loss
Bone Structure
Fruit Development, Structure, and Function
Seed Structure and Early Development of the Sporophyte
Ranks

